Results 21 to 30 of about 35,534 (303)

LRP8‐mediated selenocysteine uptake is a targetable vulnerability in MYCN‐amplified neuroblastoma

EMBO Molecular Medicine, 2023
Ferroptosis has emerged as an attractive strategy in cancer therapy. Understanding the operational networks regulating ferroptosis may unravel vulnerabilities that could be harnessed for therapeutic benefit. Using CRISPR‐activation screens in ferroptosis
H. Alborzinia, Zhiyi Chen, Umut Yildiz, F. Freitas, F. Vogel, J. Varga, Jasmin Batani, C. Bartenhagen, W. Schmitz, G. Büchel, B. Michalke, Jashuo Zheng, Svenja Meierjohann, E. Girardi, Elisa Espinet, Andrés F. Flórez, A. F. dos Santos, Nesrine Aroua, Tasneem Cheytan, Julie Haenlin, Lisa Schlicker, Thamara Nishida Xavier da Silva, A. Przybylla, Petra Zeisberger, G. Superti-Furga, M. Eilers, M. Conrad, M. Fabiano, U. Schweizer, M. Fischer, A. Schulze, A. Trumpp, J. P. Friedmann Angeli   +32 more
semanticscholar   +1 more source

MYCN and HIF-1 directly regulate TET1 expression to control 5-hmC gains and enhance neuroblastoma cell migration in hypoxia

Epigenetics, 2022
Ten-Eleven-Translocation 5-methylcytosine dioxygenases 1–3 (TET1-3) convert 5-methylcytosine to 5-hydroxymethylcytosine (5-hmC), using oxygen as a co-substrate.
Anastasia E. Hains, Sakshi Uppal, John Z. Cao, Helen R. Salwen, Mark A. Applebaum, Susan L. Cohn, Lucy A. Godley   +6 more
doaj   +1 more source

HAND2 assists MYCN enhancer invasion to regulate a noradrenergic neuroblastoma phenotype.

Cancer Research, 2023
Noradrenergic neuroblastoma (NB) is characterized by a core transcriptional regulatory circuitry (CRC) comprised of transcription factors (TFs) such as PHOX2B, HAND2 and GATA3, which form a network with MYCN.
Man Xu, Ming Sun, Xiyuan Zhang, Rosa Nguyen, Haiyan Lei, J. Shern, C. Thiele, Zhihui Liu   +7 more
semanticscholar   +1 more source

ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors

Nature Communications, 2023
CDKN2A loss and p53 mutations are rare in MYC-driven Group 3 medulloblastomas (MBs). Here the authors generated a transgenic mouse model of Group 3 MB by MYC overexpression and show that MYC suppresses ARF to drive tumorigenesis.
O. Mainwaring, Holger Weishaupt, Miao-yun Zhao, G. Rosén, Anna Borgenvik, Laura Breinschmid, Annemieke D Verbaan, Stacey Richardson, Dean Thompson, S. Clifford, Rebecca M. Hill, Karl Annusver, A. Sundström, Karl O Holmberg, M. Kasper, S. Hutter, F. Swartling   +16 more
semanticscholar   +1 more source

Epigenetic Dysregulation in MYCN-Amplified Neuroblastoma

International Journal of Molecular Sciences, 2023
Neuroblastoma (NB), a childhood cancer arising from the neural crest, poses significant clinical challenges, particularly in cases featuring amplification of the MYCN oncogene.
Soraya Epp, Shin Mei Chuah, Melinda Halasz   +2 more
semanticscholar   +1 more source

Neuroblastoma and MYCN [PDF]

Cold Spring Harbor Perspectives in Medicine, 2013
Neuroblastoma, the most common extracranial solid tumor of childhood, is thought to originate from undifferentiated neural crest cells. Amplification of the MYC family member, MYCN, is found in ∼25% of cases and correlates with high-risk disease and poor prognosis.
Huang, Miller, Weiss, William A
openaire   +4 more sources

MYCN and the epigenome [PDF]

Frontiers in Oncology, 2013
It is well known that Neuroblastoma (NB) patients whose tumors have an undifferentiated histology and a transcriptome enriched in cell cycle genes have a worse prognosis. This contrasts with the good prognoses of patients whose tumors have histologic evidence of differentiation and a transcriptome enriched in differentiation genes.
He, Stanley, Liu, Zhihui, Oh, Doo-Yi, Thiele, Carol J.   +3 more
openaire   +3 more sources

Proteogenomic characterization of cholangiocarcinoma

Hepatology, EarlyView., 2022
Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng, Peng Ran, Lingli Chen, Yunzhi Wang, Zixiang Yu, Ke Cai, Jinwen Feng, Zhaoyu Qin, Yanan Yin, Subei Tan, Yang Liu, Chen Xu, Guoming Shi, Yuan Ji, Jian‐Yuan Zhao, Jian Zhou, Jia Fan, Yingyong Hou, Chen Ding   +18 more
wiley   +1 more source

Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface [PDF]

Cancer Research, 2019
Abstract MYCN is a major driver for the childhood cancer, neuroblastoma, however, there are no inhibitors of this target. Enhanced MYCN protein stability is a key component of MYCN oncogenesis and is maintained by multiple feedforward expression loops involving MYCN transactivation target ...
Koach, J, Holien, JK, Massudi, H, Carter, DR, Ciampa, OC, Herath, M, Lim, T, Seneviratne, JA, Milazzo, G, Murray, JE, McCarroll, JA, Liu, B, Mayoh, C, Keenan, B, Stevenson, BW, Gorman, MA, Bell, JL, Doughty, L, Hüttelmaier, S, Oberthuer, A, Fischer, M, Gifford, AJ, Liu, T, Zhang, X, Zhu, S, Gustafson, WC, Haber, M, Norris, MD, Fletcher, JI, Perini, G, Parker, MW, Cheung, BB, Marshall, GM   +32 more
openaire   +5 more sources

MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma

Frontiers in Oncology, 2022
Amplification of the MYCN gene leads to its overexpression at both the mRNA and protein levels. Overexpression of MYCN mRNA may also have an important role in promoting neuroblastoma (NB) beyond the translation of MYCN protein.
Tao Liu, Lubing Gu, Zhongzhi Wu, Najah Albadari, Wei Li, Muxiang Zhou   +5 more
doaj   +1 more source